AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating ...

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating ...

OCALA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with…

AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer

AIM ImmunoTech has announced encouraging data from the ongoing Phase II trial of its Ampligen (rintatolimod) drug plus AstraZeneca's Imfinzi.The post AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer appeared first on Clinical Trials Arena.